Drugmaker’s largest deal in more than half a decade comes amid surge of M&A in sector
AbbVie has announced its acquisition of Apogee Therapeutics for $10.9 billion, marking its largest deal in over five years. This strategic move aims to expand AbbVie's portfolio with Apogee's inflammatory disease drug. The acquisition reflects a broader trend of increased merger…
Market Samachar is a news aggregator. This article was originally published by International homepage. Tap the button above to read the full story on their site.